NCT00089505View on ClinicalTrials.gov

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

PHASE3CompletedINTERVENTIONAL
Enrollment

745

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

February 28, 2011

Conditions
HIV Infections
Interventions
DRUG

Emtricitabine

200 mg taken orally

DRUG

Emtricitabine/Tenofovir disoproxil fumarate

200/300 mg taken orally

DRUG

Lopinavir/Ritonavir

400/100 mg taken orally

DRUG

Nevirapine

200 mg taken orally

DRUG

Tenofovir disoproxil fumarate

300 mg taken orally

Trial Locations (11)

4013

University of KwaZulu Natal, Durban

30100

Moi University International Clnical Trials Unit, Eldoret

Unknown

The Gaborone BHP Study Clinic, Bontleng

Molepolole BHP Study Clinic, Scottish Livingstone Hospital, Bontleng Gaborone

KMRI / Walter Reed Project Clinical Research Center, Kericho

Chris Hani Baragwanath Hospital, Johannesburg, Johannesburg

University of Witwatersrand, Johannesburg

Joint Clinical Research Centre (JCRC), Kampala

Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka

University of Zimbabwe, Avondale

(265) 175-5056

University of North Carolina Project (UNC Project), Lilongwe

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT00089505 - NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission | Biotech Hunter | Biotech Hunter